Exosome and extracellular vesicle (EV) CDMOs manufacture next-generation delivery vehicles for RNA, proteins, and small molecules. As an emerging modality, the field is still standardizing cell-source, isolation, and potency methods.
Choosing an exosome CDMO turns on cell-source and culture scale, isolation method (TFF, chromatography), characterization, and a clean regulatory record. The rankings below score each CDMO on FDA inspections, GMP certification, clinical activity, and capacity.
Sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.
Ranked by Signal Score (0–100). Fully evidenced marks a CDMO scored on all four pillars with at least one confirmed clinical program. Partly scored and profile-only CDMOs follow the scored rows. How we score
Confirm cell source and scalable culture, a robust isolation method (TFF or chromatography), qualified characterization and potency analytics, and a clean FDA and EMA/MHRA record.
Is exosome manufacturing standardized?
Not yet fully — cell-source, isolation, and potency methods are still maturing across the field, so a CDMO's specific platform and analytics maturity matter more than in established modalities.